GlassScriptPhysician profile
William A Digiacomo
NPI 1184672172
$6,887.69
in general payments reported to CMS, 2019-2025
42 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $964 · 2020: $1,068 · 2021: $1,058 · 2022: $947 · 2023: $1,356 · 2024: $860 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,833 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,832.97 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,671.94 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $910.75 | 2019-2025 | Mounjaro, Jardiance, Omvoh |
| Novo Nordisk INC | $583.69 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $509.75 | 2019-2025 | Trulance, Xifaxan |
| Abbvie INC. | $415.53 | 2021-2024 | Vraylar, Linzess, Mavyret |
| Merck Sharp & Dohme LLC | $328.83 | 2019-2023 | Verquvo, Dificid, Belsomra |
| Abbott Laboratories | $205.20 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $174.91 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $166.80 | 2019-2025 | |
| Currax Pharmaceuticals LLC | $151.13 | 2021-2025 | Contrave |
| Amarin Pharma, INC. | $150.09 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $116.44 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.10 | 2023 | |
| Horizon Therapeutics Plc | $105.63 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $99.33 | 2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $98.51 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.64 | 2020-2025 | Jardiance |
| Dexcom, INC. | $93.71 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $77.22 | 2019-2022 | |
| Allergan, INC. | $76.25 | 2020 | |
| Glaxosmithkline, LLC. | $70.85 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Genentech USA, INC. | $68.28 | 2019-2021 | |
| Nevro Corp. | $65.72 | 2024 | Senza |
| Mannkind Corporation | $57.60 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.95 | 2019-2024 | Entyvio |
| Eisai INC. | $52.80 | 2019 | |
| Janssen Biotech, INC. | $46.79 | 2022-2023 | Simponi Aria, Simponi, Stelara |
| Exact Sciences Corporation | $42.32 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $41.93 | 2022 | |
| Hikma Pharmaceuticals USA | $36.52 | 2019-2021 | |
| Globus Medical, INC. | $32.26 | 2025 | Senza |
| Teva Pharmaceuticals USA, INC. | $25.90 | 2019-2020 | |
| Alcon Vision LLC | $23.62 | 2022 | |
| Echosens North America, INC. | $17.79 | 2024 | Fibroscan |
| Gilead Sciences, INC. | $17.26 | 2024 | |
| Intercept Pharmaceuticals, INC. | $15.00 | 2019 | |
| Astellas Pharma US INC | $14.98 | 2022 | |
| Optinose US, INC. | $14.40 | 2021 | |
| Celgene Corporation | $12.99 | 2021 | |
| Biotronik INC. | $12.35 | 2020 | |
| Eyevance Pharmaceuticals LLC | $11.04 | 2021 | |
| Althera Pharmaceuticals LLC | $8.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Digiacomo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.